147 related articles for article (PubMed ID: 9706728)
1. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Kuhn W; Müller T; Gerstner A; Winkel R; Goetz ME
Can J Neurol Sci; 1998 Aug; 25(3):249-51. PubMed ID: 9706728
[TBL] [Abstract][Full Text] [Related]
2. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Husain M; Shukla R; Dikshit M; Maheshwari PK; Nag D; Srimal RC; Seth PK; Khanna VK
Neurochem Res; 2009 Aug; 34(8):1427-32. PubMed ID: 19259810
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
4. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Zeller EA; Boshes B; Arbit J; Bieber M; Blonsky ER; Dolkart M; Huprikar SV
J Neural Transm; 1976; 39(1-2):63-77. PubMed ID: 978197
[TBL] [Abstract][Full Text] [Related]
5. Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Kuiper MA; Konings CH; Bergmans PL; Wolters EC
J Neurol Sci; 1993 Jul; 117(1-2):41-5. PubMed ID: 8410065
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
7. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
8. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Götz ME; Gerstner A; Harth R; Dirr A; Janetzky B; Kuhn W; Riederer P; Gerlach M
J Neural Transm (Vienna); 2000; 107(1):41-8. PubMed ID: 10809402
[TBL] [Abstract][Full Text] [Related]
9. Platelet monoamine oxidase B activity in parkinsonian patients.
Bonuccelli U; Piccini P; Del Dotto P; Pacifici GM; Corsini GU; Muratorio A
J Neurol Neurosurg Psychiatry; 1990 Oct; 53(10):854-5. PubMed ID: 2266365
[TBL] [Abstract][Full Text] [Related]
10. Platelet phenolsulphotransferase activity in Parkinson's disease.
Glover V; Lees AJ; Ward C; Stern GM; Sandler M
J Neural Transm; 1983; 57(1-2):95-102. PubMed ID: 6578300
[TBL] [Abstract][Full Text] [Related]
11. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
[TBL] [Abstract][Full Text] [Related]
12. Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
van Kempen GM; Janjua R; Roos RA
Clin Neurol Neurosurg; 1995 May; 97(2):131-3. PubMed ID: 7656485
[TBL] [Abstract][Full Text] [Related]
13. Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls.
Finch CC; Ho SL; Williams AC; Billett EE
Prog Brain Res; 1995; 106():85-90. PubMed ID: 8584677
[No Abstract] [Full Text] [Related]
14. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
Checkoway H; Costa LG; Woods JS; Castoldi AF; Lund BO; Swanson PD
J Neural Transm Park Dis Dement Sect; 1992; 4():283-90. PubMed ID: 1388699
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
16. Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study.
Reese JP; Hamer H; Oertel WH; Strzelczyk A; Mueller UO; Heilmaier C; Kostev K
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):107-14. PubMed ID: 25546160
[TBL] [Abstract][Full Text] [Related]
17. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
Bartl J; Müller T; Grünblatt E; Gerlach M; Riederer P
J Neural Transm (Vienna); 2014 Apr; 121(4):379-83. PubMed ID: 24272680
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
19. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
20. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
Martignoni E; Blandini F; Godi L; Desideri S; Pacchetti C; Mancini F; Nappi G
Free Radic Biol Med; 1999 Aug; 27(3-4):428-37. PubMed ID: 10468218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
